JP2021524858A5 - - Google Patents

Info

Publication number
JP2021524858A5
JP2021524858A5 JP2020565903A JP2020565903A JP2021524858A5 JP 2021524858 A5 JP2021524858 A5 JP 2021524858A5 JP 2020565903 A JP2020565903 A JP 2020565903A JP 2020565903 A JP2020565903 A JP 2020565903A JP 2021524858 A5 JP2021524858 A5 JP 2021524858A5
Authority
JP
Japan
Prior art keywords
peptide
als
dose
peptide according
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565903A
Other languages
English (en)
Japanese (ja)
Other versions
JP7350019B2 (ja
JP2021524858A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2019/050619 external-priority patent/WO2019229757A1/en
Publication of JP2021524858A publication Critical patent/JP2021524858A/ja
Publication of JP2021524858A5 publication Critical patent/JP2021524858A5/ja
Application granted granted Critical
Publication of JP7350019B2 publication Critical patent/JP7350019B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565903A 2018-05-31 2019-05-30 筋萎縮性側索硬化症(als)を治療するための組成物、及び治療のためにそれを使用する方法 Active JP7350019B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862678316P 2018-05-31 2018-05-31
US62/678,316 2018-05-31
PCT/IL2019/050619 WO2019229757A1 (en) 2018-05-31 2019-05-30 Compositions and methods of using same for treating amyotrophic lateral sclerosis (als)

Publications (3)

Publication Number Publication Date
JP2021524858A JP2021524858A (ja) 2021-09-16
JP2021524858A5 true JP2021524858A5 (cg-RX-API-DMAC7.html) 2022-05-25
JP7350019B2 JP7350019B2 (ja) 2023-09-25

Family

ID=68697171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565903A Active JP7350019B2 (ja) 2018-05-31 2019-05-30 筋萎縮性側索硬化症(als)を治療するための組成物、及び治療のためにそれを使用する方法

Country Status (7)

Country Link
US (1) US20210100869A1 (cg-RX-API-DMAC7.html)
EP (1) EP3785279A4 (cg-RX-API-DMAC7.html)
JP (1) JP7350019B2 (cg-RX-API-DMAC7.html)
AU (2) AU2019277920A1 (cg-RX-API-DMAC7.html)
IL (1) IL279108B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020012532A (cg-RX-API-DMAC7.html)
WO (1) WO2019229757A1 (cg-RX-API-DMAC7.html)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
HUP0003349A3 (en) 1997-05-14 2001-12-28 Aventis Pharmaceuticals Inc Co Peptide parathyroid hormone analogs, pharmaceutical compositions comprising thereof and their use
AU8726201A (en) * 2000-03-31 2001-10-08 Smithkline Beecham Plc Use of CRF receptor agonists for the treatment of prophylaxis of diseases, for example neurodegenerative diseases
US20030140362A1 (en) * 2001-06-08 2003-07-24 Dennis Macejak In vivo models for screening inhibitors of hepatitis B virus
AU2005276117C1 (en) 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
WO2006046109A1 (en) * 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2008057609A2 (en) * 2006-11-10 2008-05-15 Genervon Biopharmaceuticals Llc Methods of treating neuronal disorders using mntf peptides and analogs thereof
CN101677948A (zh) * 2007-06-07 2010-03-24 纳斯泰克制药公司 卡贝缩宫素鼻用制剂和治疗孤独症的方法
CA2836503C (en) * 2011-05-23 2020-09-22 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2016040877A1 (en) * 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor
WO2016077687A1 (en) * 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)

Similar Documents

Publication Publication Date Title
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
JP2019196370A5 (cg-RX-API-DMAC7.html)
JP2023535744A5 (cg-RX-API-DMAC7.html)
JP2009519257A5 (cg-RX-API-DMAC7.html)
JP2016514132A5 (cg-RX-API-DMAC7.html)
JP2024518947A5 (cg-RX-API-DMAC7.html)
KR20140025314A (ko) 복합 조성물
JP2023500032A5 (cg-RX-API-DMAC7.html)
JP2022535127A5 (cg-RX-API-DMAC7.html)
JP2024529452A5 (cg-RX-API-DMAC7.html)
JP2019515909A5 (cg-RX-API-DMAC7.html)
JP2022506716A5 (cg-RX-API-DMAC7.html)
JP2015172060A5 (cg-RX-API-DMAC7.html)
RU2009118962A (ru) Применение антагонистов il-1 для лечения подагры и псевдоподагры
JP2008539273A5 (cg-RX-API-DMAC7.html)
JP2023545084A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2023546503A5 (cg-RX-API-DMAC7.html)
JP2016528171A5 (cg-RX-API-DMAC7.html)
MX2025014083A (es) Uso terapeutico de anticuerpos biespecificos anti proteina beta-amiloide (abeta)/receptor de transferrina (tfr)
JP2007501806A5 (cg-RX-API-DMAC7.html)
JP2021524858A5 (cg-RX-API-DMAC7.html)
JP2003504395A5 (cg-RX-API-DMAC7.html)
JP2023551943A5 (cg-RX-API-DMAC7.html)
JP2024512558A5 (cg-RX-API-DMAC7.html)